고혈당에 의해 유발된 인슐린저항성에 대한 Troglitazone의 효과

• Published in: Diabetes & metabolism journal Vol. 20; no. 4; pp. 361 - 366
• Main Authors: 이문규, Moon kyu Lee, 김경아, Kyung Ah Kim, 김연선, Yeon Sun Kim, 안규정, Kyu Jung Ahn, 정재훈, Jae Hoon Chung, 민용기, Yong Ki Min, 이명식, Myung Shik Lee, 김광원, Kwang Won Kim, Miles Pg, Olefsky JM
• Format: Journal Article
• Language: Korean
• Published: 대한당뇨병학회 30.12.1996
• Subjects: Free Fatty Acid; Glucose Clamp Study; Hyperglycemia; Insulin Resistance; Troglitazone
• ISSN: 2233-6079

Background: Troglitazone is a new class of oral hypoglycemic agent and improves insulin action both in NIDDM and nondiabetic insulin resistance such as fructose-fed rats. We performed this study to examine the effects of troglitazone on the nongenetic hyperglycemia-induced insulin resistance. Methods: Male Sprague-Dawley rats were divided into three groups and and were fed normal rat chow and chow admixed with troglitazone (0.2%) for 2 weeks. Rats were infused with normal saline or 30% dextrose for 6.5 hours with somatostatin (8 ug/kg/ min) followed by euglycemic hyperinsulinemic clamp study. Results: 1) There was no significant difference in body weight among three groups of rats. 2) Basal plasma glucose levels were significantly elevated in hyperglycemia group and troglitazone treated group (p < 0.05). 3) There was no significant difference in basal insuiin level among three groups of rats. 4) Maximal GDR was significantly decreased in hyperglycemia group compared to control & troglitazone treated group respectively. 5) Steady state plasma free fatty acid concentration was significantly elevated in hyperglycemia and troglitazone groups but there was no significant difference between hyperglycemia group and troglitazone treated group. Conclusion: These results suggest that 6.5 hour glucose infusion leads to significant insulin resistance and prior troglitazone treatment restores insulin action to near normal.